» Articles » PMID: 8476721

Masking of Physicians in the Growth Failure in Children with Renal Diseases Clinical Trial

Overview
Journal Pediatr Nephrol
Specialties Nephrology
Pediatrics
Date 1993 Apr 1
PMID 8476721
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Masking--hiding identities of treatments from the patient, physician and/or statistician--is a critical element in clinical trials. Wherever possible, masking is implemented to eliminate observational bias or systematic error. In this paper, general concepts of masking in clinical trials are examined. Specific masking procedures used in the "Growth Failure in Children with Renal Diseases" (GFRD) Clinical Trial are described. A method to evaluate the "success" of this masking procedure for physicians is introduced. For each randomized patient at each clinical center, the clinic director was asked to predict which treatment (1,25-dihydroxyvitamin D3 or dihydrotachysterol) was assigned. Results showed that 72% of responses initially indicated "absolutely no idea" of treatment. Additional analyses revealed that the number and percentage of "correct" guesses were essentially equal for the two treatment groups and that a patient's time on treatment did not affect the mask. We conclude that the mask of physicians in the GFRD Clinical Trial was well maintained.

Citing Articles

Interventions for metabolic bone disease in children with chronic kidney disease.

Hahn D, Hodson E, Craig J Cochrane Database Syst Rev. 2015; (11):CD008327.

PMID: 26561037 PMC: 7180137. DOI: 10.1002/14651858.CD008327.pub2.

References
1.
KROL W . The Coronary Drug Project. Closing down the study. Control Clin Trials. 1983; 4(4):505-12. DOI: 10.1016/0197-2456(83)90031-4. View

2.
Chan J, McEnery P, Brouhard B, Chinchilli V, GREIFER I . History and organization of the Growth Failure in Children with Renal Diseases Study. J Pediatr. 1990; 116(2):S3-7. DOI: 10.1016/s0022-3476(05)82915-4. View

3.
Byington R, Curb J, Mattson M . Assessment of double-blindness at the conclusion of the beta-Blocker Heart Attack Trial. JAMA. 1985; 253(12):1733-6. View

4.
Karlowski T, CHALMERS T, Frenkel L, Kapikian A, Lewis T, Lynch J . Ascorbic acid for the common cold. A prophylactic and therapeutic trial. JAMA. 1975; 231(10):1038-42. View

5.
Chan J, GREIFER I, Boineau F, MENDOZA S, McEnery P, Strife C . Rationale of the Growth Failure in Children with Renal Diseases Study. J Pediatr. 1990; 116(2):S11-6. DOI: 10.1016/s0022-3476(05)82917-8. View